PURPOSE: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. EXPERIMENTAL DESIGN: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI). RESULTS: From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor. CONCLUSIONS: CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity. Copyright (c) 2010 AACR.
PURPOSE: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. EXPERIMENTAL DESIGN: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI). RESULTS: From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor. CONCLUSIONS:CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donorCD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity. Copyright (c) 2010 AACR.
Authors: R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: C J Wu; X F Yang; S McLaughlin; D Neuberg; C Canning; B Stein; E P Alyea; R J Soiffer; G Dranoff; J Ritz Journal: J Clin Invest Date: 2000-09 Impact factor: 14.808
Authors: E P Hochberg; A C Chillemi; C J Wu; D Neuberg; C Canning; K Hartman; E P Alyea; R J Soiffer; S A Kalams; J Ritz Journal: Blood Date: 2001-08-15 Impact factor: 22.113
Authors: J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler Journal: Proc Natl Acad Sci U S A Date: 1995-08-29 Impact factor: 11.205
Authors: H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari Journal: Blood Date: 1995-09-01 Impact factor: 22.113
Authors: Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk Journal: Clin Cancer Res Date: 2017-02-13 Impact factor: 12.531
Authors: Pavan Bachireddy; Ursula Hainz; Michael Rooney; Olga Pozdnyakova; Julie Aldridge; Wandi Zhang; Xiaoyun Liao; F Stephen Hodi; Karyn O'Connell; W Nicholas Haining; Natalie R Goldstein; Christine M Canning; Robert J Soiffer; Jerome Ritz; Nir Hacohen; Edwin P Alyea; Haesook T Kim; Catherine J Wu Journal: Blood Date: 2013-12-19 Impact factor: 22.113
Authors: Ann Cai; Derin B Keskin; David S DeLuca; Anselmo Alonso; Wandi Zhang; Guang Lan Zhang; Naa Norkor Hammond; Valentina Nardi; Richard M Stone; Donna Neuberg; John Sidney; Vladimir Brusic; Catherine J Wu Journal: Clin Cancer Res Date: 2012-08-21 Impact factor: 12.531
Authors: Ute E Burkhardt; Ursula Hainz; Kristen Stevenson; Natalie R Goldstein; Mildred Pasek; Masayasu Naito; Di Wu; Vincent T Ho; Anselmo Alonso; Naa Norkor Hammond; Jessica Wong; Quinlan L Sievers; Ana Brusic; Sean M McDonough; Wanyong Zeng; Ann Perrin; Jennifer R Brown; Christine M Canning; John Koreth; Corey Cutler; Philippe Armand; Donna Neuberg; Jeng-Shin Lee; Joseph H Antin; Richard C Mulligan; Tetsuro Sasada; Jerome Ritz; Robert J Soiffer; Glenn Dranoff; Edwin P Alyea; Catherine J Wu Journal: J Clin Invest Date: 2013-08-05 Impact factor: 14.808